Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 6/20 | 0.84 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.84 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.84 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.84 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.84 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.84 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.84 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.84 |
| ▸ | HCRTR1 | O43613 | 10/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 10/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17953056 | 1.00 | CYP2C19 (0.84) | CYP2C19CYP2C9CYP2D6CYP3A4CYP1A2 | |
| Temsavir SCHEMBL30468308 | 0.91 | CYP2C19 (1.00) | CYP2C19CYP2C9CYP2D6CYP3A4CYP1A2 | |
| Temsavir SCHEMBL760768 | 0.91 | CYP2C19 (1.00) | CYP2C19CYP2C9CYP2D6CYP3A4CYP1A2 | |
| Temsavir SCHEMBL14867762 | 0.90 | CYP2C19 (0.85) | CYP2C19CYP2C9CYP2D6CYP3A4CYP1A2 | |
| SCHEMBL14754194 | 0.88 | CYP3A4 (0.68) | CYP2C19CYP2C9CYP2D6CYP3A4CYP1A2 | |
| SCHEMBL24776700 | 0.87 | CYP2C19 (0.80) | CYP2C19CYP2C9CYP2D6CYP3A4CYP1A2 | |
| SCHEMBL2629198 | 0.87 | CYP2C19 (0.80) | CYP2C19CYP2C9CYP2D6CYP3A4CYP1A2 | |
| SCHEMBL14754234 | 0.87 | CYP3A4 (0.65) | CYP2C19CYP2C9CYP2D6CYP3A4CYP1A2 | |
| SCHEMBL16618568 | 0.87 | CYP2C19 (0.73) | CYP2C19CYP2C9CYP2D6CYP3A4CYP1A2 | |
| SCHEMBL14754253 | 0.87 | CYP3A4 (0.67) | CYP2C19CYP2C9CYP2D6CYP3A4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9920073-B2 | Compositions useful for inhibiting HIV-1 infection and methods using same | DREXEL UNIVERSITY (US) | 2018-03-20 | — | — | US | disclosed |
| US-9920073-B2 | Compositions useful for inhibiting HIV-1 infection and methods using same | DREXEL UNIVERSITY (US) | 2018-03-20 | — | — | US | disclosed |
| US-9920073-B2 | Compositions useful for inhibiting HIV-1 infection and methods using same | DREXEL UNIVERSITY (US) | 2018-03-20 | — | — | US | disclosed |
| EP-2751119-B1 | FUSED BICYCLIC DIAMINE DERIVATIVES AS HIV ATTACHMENT INHIBITORS | VIIV HEALTHCARE UK NO 5 LTD (GB) | 2016-11-23 | — | — | EP | disclosed |
| US-20160214998-A1 | NOVEL COMPOSITIONS USEFUL FOR INHIBITING HIV-1 INFECTION AND METHODS USING SAME | DREXEL UNIVERSITY (US) | 2016-07-28 | — | — | US | disclosed |
| US-20160214998-A1 | NOVEL COMPOSITIONS USEFUL FOR INHIBITING HIV-1 INFECTION AND METHODS USING SAME | DREXEL UNIVERSITY (US) | 2016-07-28 | — | — | US | disclosed |
| US-20160214998-A1 | NOVEL COMPOSITIONS USEFUL FOR INHIBITING HIV-1 INFECTION AND METHODS USING SAME | DREXEL UNIVERSITY (US) | 2016-07-28 | — | — | US | disclosed |
| WO-2015051230-A1 | NOVEL COMPOSITIONS USEFUL FOR INHIBITING HIV-1 INFECTION AND METHODS USING SAME | DREXEL UNIVERSITY (US) | 2015-04-09 | — | — | WO | disclosed |
| WO-2015051230-A1 | NOVEL COMPOSITIONS USEFUL FOR INHIBITING HIV-1 INFECTION AND METHODS USING SAME | DREXEL UNIVERSITY (US) | 2015-04-09 | — | — | WO | disclosed |
| US-8835454-B2 | Fused bicyclic diamine derivatives as HIV attachment inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-16 | — | — | US | disclosed |
| US-8835454-B2 | Fused bicyclic diamine derivatives as HIV attachment inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-16 | — | — | US | disclosed |
| US-20130225635-A1 | FUSED BICYCLIC DIAMINE DERIVATIVES AS HIV ATTACHMENT INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2013-08-29 | — | — | US | disclosed |
| US-20130225635-A1 | FUSED BICYCLIC DIAMINE DERIVATIVES AS HIV ATTACHMENT INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2013-08-29 | — | — | US | disclosed |
| WO-2013033061-A1 | FUSED BICYCLIC DIAMINE DERIVATIVES AS HIV ATTACHMENT INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225635-A1 | FUSED BICYCLIC DIAMINE DERIVATIVES AS HIV ATTACHMENT INHIBITORS | CD4, GDI1, GDI2 | CYP2C19 447/4885CYP2C9 690/4885CYP2D6 310/4885 |
| US-20160214998-A1 | NOVEL COMPOSITIONS USEFUL FOR INHIBITING HIV-1 INFECTION AND METHODS USING SAME | CCL5, CCR5, CXCL10 | CYP2C19 4697/4885CYP2C9 4831/4885CYP2D6 4602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.